Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Método de diagnóstico del cáncer pancreático

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150625001
Publicado:
29/07/2015
Caducidad:
25/01/2016
Resumen:
Un grupo de investigación catalán con larga experiencia en biomarcadores del cáncer ha desarrollado un nuevo método para diagnosticar el cáncer pancreático de forma más eficiente. La tecnología combina marcadores existentes (CA19-9, CEA), otras moléculas IGF-1 y albúmina para conseguir un algoritmo que permite un diagnóstico más eficiente, distinguiendo el cáncer pancreático de la pancreatitis crónica. Se buscan empresas que trabajen en el campo de diagnóstico del cáncer interesadas en establecer acuerdos de licencia o cooperación técnica para realizar las pruebas de validación clínica finales y desarrollar el kit comercial.

Details

Tittle:
Method for the diagnosis of pancreatic cancer
Summary:
A Catalan research group with long experience in cancer biomarkers has developed a new method to diagnose more efficiently pancreatic cancer. The group is seeking companies working in cancer diagnostics for license or technical cooperation agreement to perform the final clinical validation tests and develop the comercial kit.
Description:
Nowadays, pancreatic cancer is the fourth cause of cancer death in western countries with poor prognosis due to the lack of detection techniques that do not differentiate it from other benign diseases.
The Catalan research group with deep expertise in the biochemistry of cancer has developed a new method to diagnose more efficiently pancreatic cancer. The technology relates to a combination of existing markers (CA19-9, CEA) with other molecules IGF-1 and albumin to achieve an algorithm, which allows a more efficient diagnosis distinguishing pancreatic cancer from chronic pancreatitis.
The technology has been tested in two sets of patients with pancreatitic adenocarcinoma and chronic pacreatitis obtaining very good results with high sensitivity and specificity.

The group is seeking pharmaceutical or biotech companies experienced in cancer diagnostics for license the technology or technology cooperation agreement to perfom a clinical validation test (N=150) and bring it to the market.
Advantages and Innovations:
- Efficient differential diagnosis of pancreatic cancer from chronic pancreatitis.
- Combination of clinical markers (frequently measured in clinical laboratories) with new algorithm that improve the specificity and sensitivity compared with the current markers.
- It is easily adaptable to the most common related routines in hospitals, since it is based on markers frequently used in clinical analysis
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: pharmaceutical or biotech companies.

- Specific area of activity of the partner: Cancer diagnostics

- Task to be performed by the partner sought: clinical validation test
with n=150 and further development to bring the technology to the market

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos